Strategic Diligence
Our strategic diligence practice delivers comprehensive expertise, analysis, and forecasting within a sound decision framework to clarify risks and benefits of major strategic proposals.
Representative context of our strategic diligence engagements includes:
- Partnering and strategic alliances
- In-licensing and out-licensing
- Mergers and acquisitions
- Diversifications and joint ventures
- Spin-offs and equity carve-outs
- Equity investments, asset purchases, and management buyouts
Representative scope of our strategic diligence engagements can include:
- Multiphase diligence, from initial feasibility analysis through deal valuation, structure, and closure
- Strategic objectives explication and
achievability assessment
- Technology environment forecasting
and analysis, from pharmacologic gene targets, molecular
pathways, and disease mechanisms to engineering electronic
design, mechanics, and polymers, as needed
- Clinical environment forecasting and
analysis employing evidence-based methodologies, literature
reviews, and primary research
- Product unmet medical need, practicability,
and acceptance evaluation with in-depth roundtables and
interviews among front-line and thought-leading clinicians
from all key practice settings
- Multi-scenario product performance
benchmarking and forecasting of key product features, advantages,
benefits, efficacy endpoints, and outcomes
- Clinical and epidemiologic analysis
and stratification of target patient populations, procedure
volumes, and/or product placement sites
- Clinical and preclinical development
plan milestone identification, technology risk assessment,
budgeting, and timeline estimation
- FDA approval pathway identification,
approvability assessment, and timeline estimation
- Product pricing, reimbursement, and
purchasing evaluation with in-depth roundtables and interviews
among: formulary and materials managers; P&T, capital
equipment, GPO, and coding committee members; and HCFA,
state-sponsored, and private insurance carriers.
- Product price estimation and forecasting,
from comparable and conjoint analysis through integrated
pharmacoeconomic modeling of cost-utility, cost-of-illness,
payor-stratified reimbursement, and value-based pricing.
- Multi-scenario efficacy and price-linked
potential market models
- U.S. and worldwide market penetration
and revenue models, benchmarked by product group and vertical
industry sector
- Commercial and market risk evaluation
with in-depth, confidential interviews among senior industry
executives from all key vertical industry sectors
- Manufacturing scale-up and GMP/QSR/standards
compliance assessment, budgeting, and timeline estimation
- Patents, licenses, and other intangibles
assessment and valuation
- Pro forma program and enterprise
financial modeling, including forecasts of enterprise earnings,
earnings dilution, and cash flow
- Multi-scenario equity and debt-financed
capital structure and balance sheet forecasting
- State-of-the-art modeling of shareholder value employing discounted cash flow (including program IRR and firm FCFF), real options (including compound and switching options), and comparable (including milestone-based) methodologies
|
